Alvotech adds US capacity with LOTTE Biologics
Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson’s data; Forbion’s €2.3bn funds; Alzinova rights issue.
Alvotech adds US capacity with LOTTE Biologics Beitrag lesen »
Also: BridgeBio priority review, a rival to Ascendis; Lundbeck Parkinson’s data; Forbion’s €2.3bn funds; Alzinova rights issue.
Alvotech adds US capacity with LOTTE Biologics Beitrag lesen »